Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Therapeutic vaccines against HIV infection.

García F, León A, Gatell JM, Plana M, Gallart T.

Hum Vaccin Immunother. 2012 May;8(5):569-81. doi: 10.4161/hv.19555. Review.

PMID:
22634436
2.

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.

Andrés C, Plana M, Guardo AC, Alvarez-Fernández C, Climent N, Gallart T, León A, Clotet B, Autran B, Chomont N, Gatell JM, Sánchez-Palomino S, García F.

J Virol. 2015 Sep;89(18):9189-99. doi: 10.1128/JVI.01062-15.

3.
4.

A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.

García F, Climent N, Guardo AC, Gil C, León A, Autran B, Lifson JD, Martínez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07-ORVACS Study Group..

Sci Transl Med. 2013 Jan 2;5(166):166ra2. doi: 10.1126/scitranslmed.3004682.

5.

Immunotherapy and therapeutic vaccines in HIV infection.

García F, Ruiz L, López-Bernaldo de Quirós JC, Moreno S, Domingo P.

Enferm Infecc Microbiol Clin. 2005 Jul;23 Suppl 2:84-104. Review. English, Spanish.

PMID:
16373008
6.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
7.

Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?

Vanham G, Van Gulck E.

Retrovirology. 2012 Sep 7;9:72. doi: 10.1186/1742-4690-9-72. Review.

9.

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B.

Vaccine. 2011 Jul 26;29(33):5558-66. doi: 10.1016/j.vaccine.2011.01.064.

PMID:
21300092
10.

Dendritic cell based vaccines for HIV infection: the way ahead.

García F, Plana M, Climent N, León A, Gatell JM, Gallart T.

Hum Vaccin Immunother. 2013 Nov;9(11):2445-52. Review.

11.

The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.

Palma P, Romiti ML, Li Pira G, Montesano C, Mora N, Aquilani A, Santilli V, Tchidjou HK, Ivaldi F, Giovannelli L, Pontrelli G, Borra G, Blomberg P, Gudmundsdotter L, Bråve A, Montano M, Bernardi S, Manca F, Wahren B, Rossi P.

Vaccine. 2011 Sep 9;29(39):6810-6. doi: 10.1016/j.vaccine.2010.12.058.

PMID:
21216310
12.

Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination.

Imami N, Hardy G, Burton C, Pires A, Pido-Lopez J, Moss R, Gazzard B, Gotch F.

Immunol Lett. 2001 Nov 1;79(1-2):63-76.

PMID:
11595291
13.

Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).

Boström AC, Hejdeman B, Matsuda R, Fredriksson M, Fredriksson EL, Bratt G, Sandström E, Wahren B.

Vaccine. 2004 Apr 16;22(13-14):1683-91.

PMID:
15068851
14.

Immune interventions in HIV infection.

Carcelain G, Autran B.

Immunol Rev. 2013 Jul;254(1):355-71. doi: 10.1111/imr.12083. Review.

PMID:
23772631
15.

Vaccine and immunotherapeutic interventions.

Pantaleo G, Lévy Y.

Curr Opin HIV AIDS. 2013 May;8(3):236-42. doi: 10.1097/COH.0b013e32835fd5cd. Review.

PMID:
23478912
16.

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.

Lévy Y, Gahéry-Ségard H, Durier C, Lascaux AS, Goujard C, Meiffrédy V, Rouzioux C, El Habib R, Beumont-Mauviel M, Guillet JG, Delfraissy JF, Aboulker JP; ANRS 093 Study Group..

AIDS. 2005 Feb 18;19(3):279-86.

PMID:
15718838
17.

Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.

Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, Markowitz M, Little S, Sax PE, Collier AC, Nabel G, Saindon S, Flynn T, Kuritzkes D, Barouch DH; AIDS Clinical Trials Group A5187 Team..

PLoS One. 2010 May 10;5(5):e10555. doi: 10.1371/journal.pone.0010555.

18.

[Immune-based therapies and HIV infection].

Weiss L.

Ann Med Interne (Paris). 2002 Jun;153(4):227-36. Review. French.

PMID:
12218888
19.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
20.

Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy.

Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, Echeverry M, Arango AE, Prada MC, Alarcon Hdel P, Rojas M.

Mem Inst Oswaldo Cruz. 2007 Jun;102(4):501-8.

Items per page

Supplemental Content

Support Center